Abstract. We describe the clinical and biochemical features of six men with male pseudohermaphroditism due to androgen resistance. Each of the subjects had male-gender behavior but incomplete virilization. The underlying defects in androgen metabolism were defined by studies of the 5a-reductase enzyme and the androgen receptor in fibroblasts cultured from biopsies of genital skin. Four of the six have 5a-reductase deficiency, and two have defects of the androgen receptor (the Reifenstein syndrome).
Introduction
At least three categories of defects can result in hereditary resistance to androgen action-deficiency of the 5a-reductase enzyme that converts testosterone to dihydrotestosterone in androgen target tissues, disorders of the high affinity androgen receptor protein, and abnormalities that are presumed to reside at some subsequent step in androgen action (1) . The first two categories of androgen resistance are the best understood. 5a-Reductase deficiency is an autosomal-recessive trait in which affected 46,XY individuals have normal testosteronemediated virilization of Wolffian ducts during embryogenesis but defective virilization of the external genitalia, a process that is mediated in the normal male by dihydrotestosterone. Such subjects are usually regarded as female at birth and are raised as such. At the time of expected puberty these individuals virilize partially; however, phallic enlargement, development of body and facial hair, and temporal hair regression are usually less than in normal men, ejaculatory volumes are small, and they are uniformly infertile. Before or after the commencement of virilization, affected individuals commonly undergo a change of gender role from female to male; subjects practical, is accomplished. Other patients are castrated in infancy and raised successfully as women (1) (2) (3) (4) (5) .
Disorders of the androgen receptor are inherited as Xlinked recessive traits and result in a spectrum of phenotypic manifestations, depending on the severity of impairment of receptor function. They range from 46,XY phenotypic women (complete testicular feminization) to men with severe hypospadias, infertility, and gynecomastia, commonly termed the Reifenstein syndrome, to otherwise normal men with infertility due to severe oligospermia and/or azoospermia (1) . Those subjects at the male end of this spectrum also complain of incomplete virilization, particularly of the paucity of facial and body hair and small ejaculatory volume.
Plasma testosterone levels are normal or elevated in patients with Sa-reductase deficiency and disorders of the androgen receptor (1) . Most previous studies of the effects of supraphysiological doses of androgen in subjects with disorders of the androgen receptor have provided inconsistent evidence of either biochemical or clinical benefit (6) (7) (8) (9) (10) , and the effects of supplemental androgen in 5a-reductase deficiency have not been examined systematically. We reasoned that treatment with large amounts of testosterone might result in significant acceleration of virilization in individuals with 5a-reductase deficiency who wish to function as men. Such virilization might occur on the basis of one or both of two mechanisms. First, all patients with 5a-reductase deficiency characterized to date have some residual 5a-reductase activity measurable either in tissues or in cultured fibroblasts (1, 2, (11) (12) (13) , and all have some dihydrotestosterone detectable in the circulation, albeit in subnormal levels (1) (2) (3) (4) (5) ; as a consequence, raising the plasma testosterone above the normal range might result in an increase in dihydrotestosterone formation and/or blood levels to the normal range. Second, if as has been postulated, dihydrotestosterone formation functions in the normal male only as a magnifier of a weak hormonal signal (14), a supraphysiological level of plasma testosterone might in and of itself, by mass action, act to promote virilization that could ordinarily be accomplished by much lower levels of dihydrotestosterone.
Therefore, we studied the effects of two high dose regimens of testosterone administration on nitrogen balance in four subjects with 5a-reductase deficiency and then monitored their clinical responses to long-term high dose therapy. Treatment with dihydrotestosterone itself is not practicable because it is not available in a suitable preparation. These results have been compared with similar studies in two men with incomplete male pseudohermaphroditism associated with abnormalities of the androgen receptor.
Methods
Patients. The clinical features of the six men are summarized in Table   I . C.P. and P.P. have been described previously (15) , and the characteristics of the 5a-reductase in M.M. have been described in brief (16) . The four men with 5a-reductase deficiency were reared as girls but had disturbances of gender role and identity during childhood. They all exhibited tomboyish behavior, and at some stage between ages four and ten each came to feel that he was a male but nevertheless continued to play a female role for several years. Eventually, each of the four changed gender role to that of men and claimed unequivocal male gender identity. Each of the men has heterosexual orientation. C.P. and P.P. are brothers, and another (N.A.) has two younger siblings with similar phenotypes and 5a-reductase deficiency (see Table II ). The two men with androgen receptor defects had male gender assignment and roles from birth (S.C.) or age 6 wk (B.P. double-reciprocal plots using the method of least squares. At the end of the incubations, reactions were stopped by the addition of 5 vol of chloroform/methanol (2:1). Steroids were then extracted and prepared for chromatography. 10 Mg of authentic dihydrotestosterone was added to the extracts, which were then taken to dryness, reconstituted in 20
Ml chloroform, and applied to plastic sheets (20 X 20 cm) precoated with silica gel. After chromatography in dichloromethane/ethyl acetate/ methanol (85:15:3) the steroids were visualized by spraying with water. The zone corresponding to dihydrotestosterone was cut and assayed for 3H and "4C after the addition of 10 ml of 0.4% 2,4-diphenyloxazole in toluene/methanol (10:1). 5a-Reductase activity (picomoles per hour) was calculated from the fraction of total 3H-radioactivity recovered in the dihydrotestosterone area corrected for the recovery of the [I4C]dihydrotestosterone.
To assess the stability of Sa-reductase after exposure to cycloheximide, confluent monolayers of fibroblasts were incubated with 1 mM cycloheximide for 24 h, and 5a-reductase was assayed in the standard broken cell preparation. The enzyme activity in cycloheximide-treated cells was expressed as the percentage of the activity in untreated cells of the same strain assayed at the same time.
Dihydrotestosterone binding. Cells from stock flasks were dissociated with 0.05% trypsin-0.02% EDTA at 370C for 3 min and seeded (day 0) in 60-mm diam wells in Linbro multiwell plates at a concentration of 150,000 cells in 8 ml of medium containing 10% newborn calf serum. On day 3 the medium was removed and replaced with the same volume of fresh medium with serum. On day 6 the monolayers were rinsed with 2 ml of phosphate-buffered saline, and 8 ml of medium without serum were added. On day 7 the medium was removed, and the monolayers were rinsed once with 2 ml of medium without serum and then incubated with various concentrations of [3Hldihydrotestosterone (0.2-3 nM) in medium without serum with or without a 250-fold excess of nonradioactive dihydrotestosterone. The standard assay was carried out at 37°C in a 5% CO2 incubator for 60 min. In experiments at 42°C the monolayers were preincubated at 42°C for 30 min in medium without serum; the medium was removed, and medium containing [3H]dihydrotestosterone (also warmed at 42°C) was added. The monolayers were then incubated for 60 min in the CO2 incubator at 42°C. After incubations at either 370 or 42°C the medium was removed, the monolayers were rinsed, the cells were harvested with trypsin-EDTA, and aliquots were taken for measurement of radioactivity and protein after sonication as described (19, 20 (21) . In patient S.C. the lower dose testosterone balance study was carried out before orchidectomy, and the higher dose study was performed at a later date after orchidectomy. Hormone assays. Dihydrotestosterone (DHT), testosterone (T), and estradiol (E) were assayed in isolated serum samples by using a modification of the multiple-steroid fractionation and radioimmunoassay method with correction for procedural losses as previously described (22) . In brief, steroids were separated on ethylene glycol/celite minicolumns under positive-pressure nitrogen by eluting in sequence with isooctane (10 ml), 97:3 cyclohexane/benzene (8 ml), 15% ethyl acetate in isooctane (5 ml) , and 30% ethyl acetate in isooctane (5 ml). The following I-ml fractions inclusive were collected: 4-7 for DHT; 13-17 for T; and 24-28 for E. After evaporation and reconstitution in gelatin assay buffer (1 ml for DHT and T, 0.6 ml for E), aliquots were counted for recovery, and 100-,d duplicates were assayed using highly specific antisera. Blanks were not significantly different from zero; intraassay variation was <12.5%, and interassay variation was <10% for pools of male serum. Luteinizing hormone (LH) and folliclestimulating hormone (FSH) were measured by specific radioimmunoassay in the same samples described above using Medical Research Council (Britain) standards 68/40 for LH and 69/104 for FSH.
1. Abbreviations used in this paper: DHT, dihydrotestosterone; E, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; LHRH, LH releasing hormone; TESH, 10 mM Tris-Cl, I mM EDTA, and 12 mM monothioglycerol, pH 7.4.
Results
Enzyme and receptor studies (Table II) Studies of Sa-reductase activity and the high affinity androgen receptors in fibroblasts cultured from biopsies of the scrotum from the four men with 5a-reductase deficiency, the affected siblings of N.A., and the two individuals with defects of the androgen receptor are summarized in Table II . In two of the families with 5a-reductase deficiency (C.P. (I 1-13, 16, 23) , i.e., enzyme activity in the standard assay is low, and the residual activity exhibits a high apparent Km for testosterone and a normal apparent Km for NADPH. In the subject from the third family (M.M.), the 5a-reductase exhibited features indicative of a qualitatively abnormal enzymenamely, low but measurable activity that exhibits abnormal apparent Km's for both testosterone and NADPH and is unstable in the presence of cycloheximide; these findings are similar to those previously observed in another family with Sa-reductase deficiency (24) . In all subjects with 5a-reductase deficiency the amounts of high affinity androgen receptor were normal.
The androgen receptor defects in the other two subjects were of two types. One (S.C.) had a diminished amount of androgen receptor, a finding similar to that observed in other patients with the Reifenstein phenotype (1, 17, (19) (20) ; the amount of receptor was too low to be characterized further. In this patient, 5a-reductase activity was also lower than average, a finding that has been observed on occasion in subjects with androgen-receptor defects (25) and in fibroblasts cultured from the subjects (12) . In the other man with an androgen receptor defect (B.P.), the androgen receptor was normal in amount but qualitatively abnormal, in that it was unstable to ultracentrifugation, a phenomenon observed in some other subjects with androgen resistance (18) . Nitrogen balance response to testosterone
All six of the subjects demonstrated retention of nitrogen during the short-term periods of testosterone treatment (Table  III) and developed greater degrees of nitrogen retention on the higher dose of testosterone than on the lower dose. This group included the four men with Sa-reductase deficiency and both men with abnormalities of the androgen receptor.
Endocrine investigations
Basal plasma testosterone concentrations were in the normal range in the four subjects with Sa-reductase deficiency, and plasma dihydrotestosterone levels were in the low normal range (Table IV) . B.P. had low basal testosterone levels thought to be secondary to previous orchiopexy and episodes of 23 . However, before orchidectomy, normal levels of plasma 1 7#-hydroxy androgens (which measures testosterone predominantly, using competitive protein binding) had been recorded on several occasions (10.2-14 ng/ml; normal adult male 4.9-21 ng/ml). Dihydrotestosterone levels were low in the two patients with receptor defects, in part at least because of the low levels of plasma testosterone. On therapy with high doses of testosterone, dihydrotestosterone levels in all six subjects were in or above the normal range.
Basal gonadotropin levels were elevated in two of the subjects with 5a-reductase deficiency, and the response of plasma LH to 100 Atg intravenous luteinizing hormone releasing hormone (LHRH) was amplified in one of the two subjects tested. Basal levels of LH suppressed in the first few days of testosterone therapy in all but one (N.A.) of the patients with 5a-reductase deficiency and was suppressed in all four on long-term, high dose testosterone therapy. Subject S.C. had LH levels in the upper normal range before orchidectomy (mean±SE 9.5±0.4 U/liter, n = 12) and an exaggerated response of plasma LH to intravenous LHRH; LH levels rose after orchidectomy and did not decrease during the acute studies with testosterone or on long-term therapy with high doses of testosterone. In B.P. plasma LH levels were elevated during the acute studies with both dose levels of testosterone propionate but fell to the normal range after long-term testosterone ester therapy.
Basal plasma estradiol levels were normal in three of the subjects with Sa-reductase deficiency but high in N. Table V ). All four subjects with 5a-reductase deficiency had beneficial clinical responses to long-term high dose parenteral androgen therapy as evidenced by improvement in virilization. Enlargement of the penile shaft was recorded with an increase both in length and circumference although the glans did not enlarge in any patient. Erectile potency improved in each, and an increase in ejaculatory volume was reported by three subjects. Muscle bulk increased, and facial and body hair were more masculine (Fig. 1) . All of the men with Sa-reductase deficiency developed transient acne, two developed mild gynecomastia while on long-term treatment, and all reported an improved feeling of well-being. Similar changes were noted in one man (B.P.) with a receptor defect. S.C. noted improved well-being and muscle strength but achieved insignificant virilization of the genitalia and sexual hair and only a slight increase in potency; these inadequate responses occurred despite having similar circulating plasma testosterone and dihydrotestosterone levels and equally positive nitrogen retention as the other subjects. There was no improvement in sperm count in any of the six patients while on testosterone therapy.
Improved erectile potency and secondary sexual characteristics were maintained in the four patients with 5a-reductase deficiency on oral testosterone undecanoate, although testosterone levels were not as high on this regimen and LH levels were elevated as compared with those while on long-term parenteral testosterone ester therapy. Nevertheless the circulating dihydrotestosterone levels on testosterone undecanoate were maintained within or above the normal range.
Discussion
Our six patients with male pseudohermaphroditism fulfill the phenotypic and endocrine criteria for the diagnosis of androgen resistance (1) . The clinical features of the four men with 5a-reductase deficiency (and of two siblings of one of the subjects) conform to those reported elsewhere, namely a disorder in which there is normal mullerian duct regression, normal virilization of Wolffian duct structures, and incomplete virilization of the external genitalia and urogential sinus (1) (2) (3) (4) (5) . As in the other reported cases, significant virilization of the external genitalia as well as development of some secondary sexual characteristics occurred at the time of expected puberty. Seminal fluid analyses revealed severe oligospermia or azoospermia. The diagnosis of 5a-reductase deficiency can be made by measuring the ratio of plasma testosterone to dihydrotestosterone or the ratio of urinary etiocholanolone to androsterone (1) (2) (3) (4) (5) . Low-normal plasma dihydrotestosterone levels (in the presence of a normal plasma testosterone) were present in the subjects with Sa-reductase deficiency, and the ratios of plasma testosterone to dihydrotestosterone were higher than in controls. The diagnosis can also be established, as was done in our subjects, by characterizing the level and qualitative features of the enzyme in fibroblasts cultured from genital skin. Two of our three families with Sa-reductase deficiency have very low activities of Sa-reductase, similar to the findings observed in the Dallas and the Dominican Republic families (23) . M.M. had low but measurable 5a-reductase activity and exhibited abnormal apparent Km's for both testosterone and NADPH and instability in the presence of cycloheximide, a qualitative defect of the enzyme similar to that reported in a previous family with Sa-reductase deficiency (23) . Thus, the subjects reported here fulfill phenotypic, endocrine, and biochemical features of Sa-reductase deficiency (1-5).
The clinical features of patients B.P. and S.C. are characteristic of androgen receptor abnormalities (1) . Studies of the androgen receptor in genital skin fibroblasts from B.P. revealed normal amounts of a qualitatively abnormal receptor whereas S.C. has a deficiency of androgen receptors in cultured skin fibroblasts.
High dose testosterone administration, sufficient to raise plasma testosterone concentrations to levels above the upper limit of the normal adult male range, resulted in short-term positive nitrogen balance and a long-term enhancement of virilization in all four subjects with 5a-reductase deficiency. We believe that this is the first time the effects of such a therapeutic maneuver have been systematically investigated in this condition. The modest phallic growth, the development of hair on the trunk, face, and extremities, and the increased potency and ejaculatory volume have been gratifying to these subjects, and each has reported a more satisfactory sexual performance and a marked improvement in their self-images as men. The latter features of course are difficult to assess in quantitative terms, and indeed a placebo effect may play a major role in such phenomena, as evidenced by the fact that subject S.C. who had no clear-cut objective evidence of increased virilization reported an increased frequency of masturbation. Virilization has been maintained with amounts of oral testosterone undecanoate that result in lower plasma testosterone levels than on high dose testosterone therapy but normal or elevated dihydrotestosterone concentrations. The discrepancy between plasma testosterone and plasma dihydrotestosterone levels has been described previously in men receiving testosterone undecanoate (26, 27) .
The mechanism by which testosterone promotes nitrogen balance and virilization in subjects with 5a-reductase deficiency is not resolved by the present study. The effect may be mediated by dihydrotestosterone formed by the small amount of residual Sa-reductase in such subjects (1, (11) (12) (13) since plasma dihydrotestosterone levels rose into the normal range on treatment. Alternatively, massive plasma and tissue levels of testosterone may saturate the androgen receptor (14) and thereby promote androgen action directly. The androgen receptor binds both testosterone and dihydrotestosterone; however, the affinity for dihydrotestosterone is much greater than for testosterone (14) . It is of interest that the degree of positive nitrogen balance achieved in these subjects is of approximately the same magnitude as has previously been observed in normal men given large doses of testosterone propionate (28) (29) (30) (31) . In normal men the positive nitrogen balance after supplemental androgen therapy is temporary (28) (29) (30) . We do not know whether the positive balance was temporary or sustained in our subjects; however, the growth of facial and body hair has been progressive during the course of these studies, and the improvements in phallic size and muscle bulk have been maintained.
The finding in the present study that high dose testosterone therapy resulted in positive nitrogen balance in the two men with receptor abnormalities was unexpected. Most previous studies in patients with complete testicular feminization have failed to show nitrogen retention or clinical evidence of virilization when supplemental androgen therapy was administered (6) (7) (8) (9) . However, Rosenfield et al. (10) described one subject with incomplete male pseudohermaphroditism and androgen resistance who developed positive urinary nitrogen retention when plasma androgens were raised above the physiological range. The development of short-term positive nitrogen balance in S.C., even though long-term improvement in male secondary sex characteristics failed to occur on exogenous androgens, indicates a dissociation of effects that are not explained by current knowledge. Since the outcome in these patients cannot be predicted by short-term studies of nitrogen balance, treatment with supraphysiological doses of androgens should be considered in all men with androgen receptor defects who exhibit inadequate virilization.
Basal LH levels are sometimes elevated and sometimes normal in 5a-reductase deficiency, suggesting that dihydrotestosterone may mediate in part the negative feedback of testosterone at the hypothalamic-pituitary level (1) (2) (3) (4) (5) . The exaggerated response of plasma LH to the administration of LHRH in one of the men with Sa-reductase deficiency is in keeping with this interpretation. As would be expected, basal plasma LH levels and the response to LHRH are usually elevated in subjects with male pseudohermaphroditism due to receptor defects (7) .
The response in these subjects of plasma gonadotropins to both short-and long-term testosterone therapy deserves comment. In all five subjects who responded to androgen therapy by clinical and laboratory criteria, plasma LH and FSH levels were eventually suppressed to normal or subnormal levels.
This response may therefore be used as a predictor ofsubsequent responsiveness to testosterone therapy. In each instance, this fall was accompanied by and/or preceded by increases in The change of gender-role behavior in the subjects with 5a-reductase deficiency has previously been described in subjects with Sa-reductase deficiency and other forms of male pseudohermaphroditism (4, 35) . All four of the men with Sareductase deficiency were identified as females at birth but described an early change in gender identity before noticing virilization at the time of expected puberty. All four lived in communities where rigorous conformity with a prescribed gender role was expected and gender change difficult. However, these men, who were reared and lived as females until they were between 14 and 24 yr, were able to overcome both the social and legal barriers to such a change and make successful adjustments to roles that conform to their genetic, endocrine, and psychological sex. It is not known whether this change in gender role is the result of a true change in gender identity or merely the resolution of a confusion as to gender identity consequent to the genital ambiguity that is present from birth (35) . An equally attractive possibility is that male gender identity might be imprinted before or immediately after birth by androgens themselves (35) .
The findings in the present studies indicate that long-term treatment with supraphysiological doses of testosterone may be of benefit in partially repairing the incomplete virilization, and in improving the self-image of masculinity in men with Sa-reductase deficiency and, in selected instances, of men with defects of the androgen receptor. To date, no adverse effects of this regimen have been noted, but it is important to follow 150S High Dose Androgen Therapy in Sa-Reductase Deficiency such individuals closely as long as they are on such a regimen.
Androgen therapy is not appropriate in individuals with either syndrome who have female behavior patterns.
